FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309189148> ?p ?o ?g. }

• W4309189148 abstract "Dysregulation of the BCL-2 family is implicated in protecting chronic myeloid leukemia (CML) cells from intracellular damage and BCR::ABL1-inhibition with tyrosine kinase inhibitors (TKIs) and may be a viable therapeutic target in blast phase (BP-)CML, for which treatment options are limited. BH3 mimetics, a class of small molecule inhibitors with high-specificity against the prosurvival members of the BCL-2 family, have displayed clinical promise in the treatment of chronic lymphocytic and acute myeloid leukemia as single agents and in combination with standard-of-care therapies. Here we present the first comparison of inhibition of BCL-2 prosurvival proteins BCL-2, BCL-xL and MCL-1 in combination with a second or third generation TKI, crucially with comparisons drawn between myeloid and lymphoid BP-CML samples. Co-treatment of four BP-CML cell lines with the TKIs nilotinib or ponatinib and either BCL-2 (venetoclax), MCL-1 (S63845) or BCL-xL (A-1331852) inhibitors resulted in a synergistic reduction in cell viability and increase in phosphatidylserine (PS) presentation. Nilotinib with BH3 mimetic combinations in myeloid BP-CML patient samples triggered increased induction of apoptosis over nilotinib alone, and a reduction in colony-forming capacity and CD34+ fraction, while this was not the case for lymphoid BP-CML samples tested. While some heterogeneity in apoptotic response was observed between cell lines and BP-CML patient samples, the combination of BCL-xL and BCR::ABL1 inhibition was consistently effective in inducing substantial apoptosis. Further, while BH3 mimetics showed little efficacy as single agents, dual-inhibition of BCL-2 prosurvival proteins dramatically induced apoptosis in all cell lines tested and in myeloid BP-CML patient samples compared to healthy donor samples. Gene expression and protein level analysis suggests a protective upregulation of alternative BCL-2 prosurvival proteins in response to BH3 mimetic single-treatment in BP-CML. Our results suggest that BH3 mimetics represent an interesting avenue for further exploration in myeloid BP-CML, for which alternative treatment options are desperately sought." @default.
• W4309189148 created "2022-11-24" @default.
• W4309189148 creator A5017296720 @default.
• W4309189148 creator A5057534414 @default.
• W4309189148 creator A5062780481 @default.
• W4309189148 creator A5067693625 @default.
• W4309189148 creator A5069956148 @default.
• W4309189148 creator A5072637924 @default.
• W4309189148 creator A5081213425 @default.
• W4309189148 creator A5088647683 @default.
• W4309189148 date "2022-11-15" @default.
• W4309189148 modified "2023-10-08" @default.
• W4309189148 title "BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia" @default.
• W4309189148 cites W1490860457 @default.
• W4309189148 cites W1679250118 @default.
• W4309189148 cites W1933867057 @default.
• W4309189148 cites W1964625584 @default.
• W4309189148 cites W1973300535 @default.
• W4309189148 cites W1976197588 @default.
• W4309189148 cites W1977258127 @default.
• W4309189148 cites W1982590492 @default.
• W4309189148 cites W1985182434 @default.
• W4309189148 cites W1991455654 @default.
• W4309189148 cites W2003925746 @default.
• W4309189148 cites W2003973314 @default.
• W4309189148 cites W2013658560 @default.
• W4309189148 cites W2031641885 @default.
• W4309189148 cites W2034862875 @default.
• W4309189148 cites W2037945038 @default.
• W4309189148 cites W2038683465 @default.
• W4309189148 cites W2044833176 @default.
• W4309189148 cites W2047122678 @default.
• W4309189148 cites W2057375535 @default.
• W4309189148 cites W2077945404 @default.
• W4309189148 cites W2110648386 @default.
• W4309189148 cites W2112127173 @default.
• W4309189148 cites W2124196948 @default.
• W4309189148 cites W2129216024 @default.
• W4309189148 cites W2136910701 @default.
• W4309189148 cites W2139594142 @default.
• W4309189148 cites W2141795335 @default.
• W4309189148 cites W2150680216 @default.
• W4309189148 cites W2160075057 @default.
• W4309189148 cites W2172242534 @default.
• W4309189148 cites W2224782492 @default.
• W4309189148 cites W2339635189 @default.
• W4309189148 cites W2534349779 @default.
• W4309189148 cites W2769954801 @default.
• W4309189148 cites W2901551508 @default.
• W4309189148 cites W2969303401 @default.
• W4309189148 cites W2980622391 @default.
• W4309189148 cites W2997600890 @default.
• W4309189148 cites W3009751715 @default.
• W4309189148 cites W3014686038 @default.
• W4309189148 cites W3036921114 @default.
• W4309189148 cites W3097977878 @default.
• W4309189148 cites W3130755949 @default.
• W4309189148 cites W3162288448 @default.
• W4309189148 doi "https://doi.org/10.1038/s41420-022-01211-1" @default.
• W4309189148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36379918" @default.
• W4309189148 hasPublicationYear "2022" @default.
• W4309189148 type Work @default.
• W4309189148 citedByCount "2" @default.
• W4309189148 countsByYear W43091891482023 @default.
• W4309189148 crossrefType "journal-article" @default.
• W4309189148 hasAuthorship W4309189148A5017296720 @default.
• W4309189148 hasAuthorship W4309189148A5057534414 @default.
• W4309189148 hasAuthorship W4309189148A5062780481 @default.
• W4309189148 hasAuthorship W4309189148A5067693625 @default.
• W4309189148 hasAuthorship W4309189148A5069956148 @default.
• W4309189148 hasAuthorship W4309189148A5072637924 @default.
• W4309189148 hasAuthorship W4309189148A5081213425 @default.
• W4309189148 hasAuthorship W4309189148A5088647683 @default.
• W4309189148 hasBestOaLocation W43091891481 @default.
• W4309189148 hasConcept C126322002 @default.
• W4309189148 hasConcept C170493617 @default.
• W4309189148 hasConcept C203014093 @default.
• W4309189148 hasConcept C2777413986 @default.
• W4309189148 hasConcept C2777583451 @default.
• W4309189148 hasConcept C2778729363 @default.
• W4309189148 hasConcept C2779282312 @default.
• W4309189148 hasConcept C2780381907 @default.
• W4309189148 hasConcept C42362537 @default.
• W4309189148 hasConcept C502942594 @default.
• W4309189148 hasConcept C71924100 @default.
• W4309189148 hasConcept C98274493 @default.
• W4309189148 hasConceptScore W4309189148C126322002 @default.
• W4309189148 hasConceptScore W4309189148C170493617 @default.
• W4309189148 hasConceptScore W4309189148C203014093 @default.
• W4309189148 hasConceptScore W4309189148C2777413986 @default.
• W4309189148 hasConceptScore W4309189148C2777583451 @default.
• W4309189148 hasConceptScore W4309189148C2778729363 @default.
• W4309189148 hasConceptScore W4309189148C2779282312 @default.
• W4309189148 hasConceptScore W4309189148C2780381907 @default.
• W4309189148 hasConceptScore W4309189148C42362537 @default.
• W4309189148 hasConceptScore W4309189148C502942594 @default.
• W4309189148 hasConceptScore W4309189148C71924100 @default.
• W4309189148 hasConceptScore W4309189148C98274493 @default.
• W4309189148 hasFunder F4320307874 @default.
• W4309189148 hasFunder F4320319985 @default.

• next